MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Kodu・Aktsiate loetelu・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Suletud

18.25 15.8

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

15.76

Max

18.44

Põhinäitajad
By Trading Economics
Sissetulek	35M 9.5M
Müük	35M 94M
Kasumimarginaal	10.158
Töötajad	619
EBITDA	35M 17M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+26.88% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	10. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-172M 2.5B
Eelmine avamishind	2.45
Eelmine sulgemishind	18.25

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

8.81 / 10.18 Toetus ja vastupanu

Adaptive Biotechnologies Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. jaan 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12. jaan 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12. jaan 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12. jaan 2026, 23:18 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12. jaan 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12. jaan 2026, 21:50 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

12. jaan 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12. jaan 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12. jaan 2026, 20:54 UTC

Tulu

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12. jaan 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12. jaan 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12. jaan 2026, 20:18 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12. jaan 2026, 20:18 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12. jaan 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12. jaan 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12. jaan 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. jaan 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12. jaan 2026, 19:24 UTC

Omandamised, ülevõtmised, äriostud

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12. jaan 2026, 19:22 UTC

Omandamised, ülevõtmised, äriostud

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12. jaan 2026, 18:21 UTC

Omandamised, ülevõtmised, äriostud

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12. jaan 2026, 18:20 UTC

Omandamised, ülevõtmised, äriostud

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12. jaan 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12. jaan 2026, 18:16 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12. jaan 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12. jaan 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12. jaan 2026, 18:01 UTC

Omandamised, ülevõtmised, äriostud

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12. jaan 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Adaptive Biotechnologies Corp Prognoos

Hinnasiht

By TipRanks

26.88% tõus

12 kuu keskmine prognoos

Keskmine 20.25 USD 26.88%

Kõrge 21 USD

Madal 20 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Adaptive Biotechnologies Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Adaptive Biotechnologies Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

8.81 / 10.18Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.